ivonescimab + AK117 + albumin-bound paclitaxel + gemcitabine

This is a **four-drug investigational combination therapy** under evaluation primarily for the treatment of metastatic pancreatic cancer and triple-negative breast cancer. The regimen consists of: - **ivonescimab**: a bispecific monoclonal antibody targeting PD-1 and VEGF, developed to combine immunotherapy (checkpoint blockade) with anti-angiogenic activity. - **AK117 (ligufalimab)**: a humanized IgG4 monoclonal antibody targeting CD47, designed to block the “don’t eat me” signal and promote phagocytosis of tumor cells. - **albumin-bound paclitaxel**: a chemotherapeutic agent enhancing paclitaxel delivery and efficacy. - **gemcitabine**: a nucleoside analog used as chemotherapy for various cancers. The combination aims to synergistically harness checkpoint inhibition, anti-angiogenesis, immune cell phagocytosis, and cytotoxic chemotherapy. Akeso is the developer for both ivonescimab and AK117. This combination is being investigated in **Phase 3 clinical trials** for metastatic pancreatic cancer and has been studied in triple-negative breast cancer[2][8][7].

Other names

ligufalimabAbraxane